Nonetheless, localized delivery is feasible only for accessible or early-stage tumors and is impractical for metastatic or deeply seated cancers—particularly those such as gliomas or disseminated gastrointestinal tumors, where KIF4A is highly oncogenic. This evidence concerns the gene KIF4A and central nervous system cancer.